Key clinical point: Adding bevacizumab to erlotinib failed to improve outcomes in advanced epidermal growth factor receptor–mutant non–small cell lung cancer.
Major finding: Median progression-free survival was 17.9 months with bevacizumab-erlotinib combination therapy and 13.5 months with erlotinib monotherapy (hazard ratio, 0.81; P = .39).
Study details: A multicenter, phase 2, randomized, controlled trial among 88 patients with stage 4 non–small cell lung cancer harboring an epidermal growth factor receptor mutation.
Disclosures: Dr. Stinchcombe reported no relevant conflicts of interest. The trial was supported by Genentech/Roche.
Stinchcombe TE et al. JAMA Oncol. 2019 Aug 8. doi: 10.1001/jamaoncol.2019.1847.